ClinicalTrials.gg
CompletedNCT01408082DOUBleUpdated Nov 19, 2021

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

A Phase 3 interventional study of ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) and Azasite in Blepharitis, sponsored by Sun Pharmaceutical Industries Limited. Completed at 45 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
917
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.

02

Conditions studied

  • Blepharitis

Browse trials for

03

In context

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

This study's enrollment of 917 is above the median of 60 across 65 interventional studies indexed under Blepharitis.

Browse Blepharitis studies →

Lead sponsor

Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years of age at Visit 1 (Day 1, Baseline) of either sex and any race.
  • Signature of the subject or legally authorized representative on the Form.
  • Are willing and able to follow all instructions and attend all study visits.
  • Are willing to avoid disallowed medication for the duration of the study.
  • If female is of , agree to and submit a urine sample for pregnancy testing. Post menopausal is defined as having no menses for at least 12 consecutive months.
  • Additional inclusion criteria also apply.

Exclusion criteria

Exclusion Criteria:

  • Have known sensitivity or poor tolerance to any component of the Drug.
  • Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation other than Blepharitis in the study eye.
  • Have used topical medications or topical ophthalmic solutions that the investigator feels may interfere with the study parameters.
  • Have used any non-diagnostic topical ophthalmic solutions in the study eye.
  • Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive urine pregnancy test.
  • Currently suffer from alcohol and/or drug abuse.
  • Have prior (within 30 days of beginning dosing) or anticipated concurrent use of an investigational drug or device.
  • Have a condition or a situation which, in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
  • Additional exclusion criteria also apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
917 participants (actual)

Study arms

  • Experimental
    ISV-502

    Drug: ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)

  • Active comparator
    AzaSite

    Drug: Azasite

  • Active comparator
    Dexamethasone

    Drug: Dexamethasone

  • Placebo comparator
    Vehicle

    Other: Vehicle

Interventions

  • DrugISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)

    Azithromycin and Dexamethasone twice daily for 2 weeks

    Also known as: AzaSite Plus

  • Azasite twice daily for 2 weeks

  • Dexamethasone twice daily for 2 weeks

  • OtherVehicle

    Vehicle twice daily for 2 weeks

06

What researchers measure

Primary outcomes

  1. Clinical Resolution

    The primary efficacy endpoint for the comparison of ISV-502 and AzaSite is complete clinical resolution of signs and symptoms at Day 15.

    Time frame: Day 15

  2. Recurrence of Clinical Signs and Symptoms

    The primary efficacy endpoint for the comparison of ISV-502 and Dexamethasone is recurrence of clinical signs and symptoms by 6-Month Follow-up.

    Time frame: 6 Month

07

Study locations

45 sites
  • Arizona Eye Center
    Chandler, Arizona, United States
  • Arizona Center for Clinical Trials LLC
    Phoenix, Arizona, United States
  • Cornea Consultants of Arizona
    Phoenix, Arizona, United States
  • Lugene Eye Institute
    Glendale, California, United States
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • Macy Eye Center
    Los Angeles, California 90048, United States
  • North Valley Eye Medical Group, Inc.
    Mission Hills, California, United States
  • Eye Research Foundation
    Newport Beach, California, United States
  • North Bay Associates, Inc.
    Petaluma, California, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Shasta Eye Medical Group, Inc.
    Redding, California, United States
  • San Diego Eye and Laser Center
    San Diego, California 92123, United States
  • West Coast Eye Care Associates
    San Diego, California, United States
  • Florida Eye Microsurgicial Institute, Inc.
    Boynton Beach, Florida, United States
  • ZASA Clinical Research, LLC
    Boynton Beach, Florida, United States
  • Magruder Eye Institute
    Orlando, Florida, United States
  • Vision Eye Care Center
    Palm Springs, Florida, United States
  • International Research Center
    Tampa, Florida, United States
  • Richard Eiferman, MD
    Louisville, Kentucky, United States
  • Lakeview Optical
    Gretna, Louisiana, United States
  • Center for Sight, Inc.
    Fall River, Massachusetts 02720, United States
  • Tauber Eye Center
    Kansas City, Missouri, United States
  • Ophthalmology Associates
    Saint Louis, Missouri, United States
  • Comprehensive Eye Care Ltd
    Washington, Missouri, United States
  • Abrams Eye Institute
    Las Vegas, Nevada, United States
  • Nevada Eye Care Professionals
    Las Vegas, Nevada, United States
  • Eye Care Associates of Nevada
    Sparks, Nevada, United States
  • David Ringel, OD PA
    Sewell, New Jersey, United States
  • Ophthalmic Consultants of Long Island
    Lynbrook, New York, United States
  • Ophthalmic Consultants of Long Island
    Rockville Centre, New York, United States
  • Ophthalmic Consultants of Long Island
    Valley Stream, New York, United States
  • South Shore Eye Care
    Wantagh, New York, United States
  • Charlotte Eye Ear Nose & Throat Associates, P.A.
    Charlotte, North Carolina, United States
  • Mundorf Eye Center
    Charlotte, North Carolina, United States
  • James Branch, MD
    Winston-Salem, North Carolina, United States
  • Eye Care Associates of Greater Cincinnati, Inc.
    Cincinnati, Ohio, United States
  • Eye Care Associates of Greater Cincinnati, Inc.
    Fairfield, Ohio, United States
  • Eye Care Associates of Greater Cincinnati, Inc.
    Madeira, Ohio, United States
  • Roseburg Research Associates, LLC
    Roseburg, Oregon 97471, United States
  • Philadelphia Eye Associates
    Philadelphia, Pennsylvania, United States
  • Research Across America @ Wyomissing Optometric Center Inc
    Wyomissing, Pennsylvania, United States
  • Total Eye Care, PA
    Memphis, Tennessee, United States
  • David Shulman, MD
    San Antonio, Texas, United States
  • Sun Research Institute
    San Antonio, Texas, United States
  • Daynes Eye and Lasik
    Salt Lake City, Utah 84103, United States
08

References and documents

Publications

  • Hosseini K, Bourque LB, Hays RD. Development and evaluation of a measure of patient-reported symptoms of Blepharitis. Health Qual Life Outcomes. 2018 Jan 11;16(1):11. doi: 10.1186/s12955-018-0839-5. PubMed 29325546 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01408082
Responsible party
Sponsor
First posted
Aug 3, 2011
Start date
Oct 2011
Primary completion
Mar 2013
Completion
Jun 2013
Last update
Nov 19, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion